Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging: a 12-week randomized double-blind placebo controlled trial

详细信息    查看全文

• 作者：Nilanjana Bose ; James Bena ; Soumya Chatterjee
• 刊名：Arthritis Research & Therapy
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：17
• 期：1
• 全文大小：509 KB
• 参考文献：1. LeRoy, EC, Black, C, Fleischmajer, R, Jablonska, S, Krieg, T, Medsger, TA (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15: pp. 202-5
  2. Korn, JH, Mayes, M, Matucci, CM, Rainisio, M, Pope, J, Hachulla, E (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50: pp. 3985-93 CrossRef
  3. Steen V, Denton CP, Pope JE, Matucci-Cerinic M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford). 2009;48:iii19-4.
  4. Campbell, PM, LeRoy, EC (1975) Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 4: pp. 351-68 CrossRef
  5. Yamane, K, Miyauchi, T, Suzuki, N, Yuhara, T, Akama, T, Suzuki, H (1992) Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 19: pp. 1566-71
  6. Biondi, ML, Marasini, B, Bassani, C, Agastoni, A (1991) Increased plasma endothelin levels in patients with Raynaud's phenomenon. N Engl J Med 324: pp. 1139-40
  7. Cardillo, C, Schinzari, F, Melina, D, Mores, N, Bosello, S, Peluso, G (2009) Improved endothelial function after endothelin receptor blockade in patients with systemic sclerosis. Arthritis Rheum 60: pp. 1840-4 CrossRef
  8. Sfikakis, PP, Papamichael, C, Stamatelopoulos, KS, Tousoulis, D, Fragiadaki, KG, Katsichti, P (2007) Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 56: pp. 1985-93 CrossRef
  9. Matucci-Cerinic, M, Denton, CP, Furst, DE, Mayes, MD, Hsu, VM, Carpentier, P (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70: pp. 32-8 CrossRef
  10. Correa, MJ, Andrade, LE, Kayser, C (2010) Comparison of laser Doppler imaging, fingertip lacticemy test, and nailfold capillaroscopy for assessment of digital microcirculation in systemic sclerosis. Arthritis Res Ther 12: pp. R157 CrossRef
  11. Al-Ashkar F, Bena J, Stelmach K, Chatterjee S. Evaluation of digital microcirculation in systemic sclerosis and Raynaud's disease using laser Doppler imaging. Arthritis Rheum. 2005;52:4078-. Abstract.
  12. Rosato, E, Rossi, C, Molinaro, I, Giovannetti, A, Pisarri, S, Salsano, F (2011) Laser Doppler perfusion imaging in systemic sclerosis impaired response to cold stimulation involves digits and hand dorsum. Rheumatology (Oxford) 50: pp. 1654-8 CrossRef
  13. Rosato, E, Borghese, F, Pisarri, S, Salsano, F (2009) Laser Doppler perfusion imaging is useful in the study of Raynaud's phenomenon and improves the capillaroscopic diagnosis. J Rheumatol 36: pp. 2257-63 CrossRef
  14. Murray, AK, Moore, TL, Manning, JB, Taylor, C, Griffiths, CE, Herrick, AL (2009) Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders. Arthritis Rheum 61: pp. 1103-11 CrossRef
  15. Murray, AK, Herrick, AL, King, TA (2004) Laser Doppler imaging: a developing technique for application in the rheumatic diseases. Rheumatology (Oxford) 43: pp. 1210-8 CrossRef
  16. Cutolo, M, Ferrone, C, Pizzorni, C, Soldano, S, Seriolo, B, Sulli, A (2010) Peripheral blood perfusion correlates with microvascular abnormalities in systemic sclerosis: a laser-Doppler and nailfold videocapillaroscopy study. J Rheumatol 37: pp. 1174-80 CrossRef
  17. Rosato, E, Molinaro, I, Borghese, F, Rossi, C, Pisarri, S, Salsano, F (2010) Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension. J Rheumatol 37
• 刊物主题：Rheumatology; Orthopedics;
• 出版者：BioMed Central
• ISSN：1478-6354

文摘

Introduction In patients with systemic sclerosis (SSc), digital ischemia results from an occlusive microvasculopathy that may not respond adequately to conventional vasodilators. Endothelin receptor antagonists can potentially modify the fibroproliferative vascular remodeling in SSc, and hence their use may be justified in the management of digital ischemia. The objective of this clinical trial was to evaluate the effect of ambrisentan, a selective endothelin type A receptor antagonist, on microvascular blood flow in patients with limited systemic sclerosis (SSc) using laser Doppler perfusion imaging (LDPI). Methods In this randomized, double-blind, placebo controlled study we enrolled 20 patients with limited SSc. Fifteen patients received ambrisentan 5 mg daily for one month and then 10 mg daily for two months, and five received a placebo. There were three visits: weeks 0 (baseline), one and 12. Three patient-oriented questionnaires were completed at each visit: Scleroderma-Health Assessment Questionnaire (S-HAQ), Raynaud Condition Score (RCS), and Pain-Visual Analog Scale (P-VAS). At each visit, LDPI was used to obtain three blood flow readings involving regions of interest in second to fifth fingers of the non-dominant hand at room temperature (25°C) and after cooling (10°C) for two minutes. Results There were 16 females (80%); mean age was 50 years. None of the differences in blood flow (as measured by LDPI) were significant both at baseline and after cooling. However, patients in the ambrisentan group showed significant improvement in the patient-oriented outcomes: RCS (P--.001) and S-HAQ score (P--.005). Conclusions This pilot study did not show evidence of significant increase in digital blood flow over time; however, there was an improvement in RCS and S-HAQ score. We conclude that continuous use of ambrisentan for three months does not seem to significantly improve digital blood flow in SSc patients. Trial registration Clinicaltrials.gov NCT01072669. Registered 19 February 2010.